Payers see price leverage with entry of Merck hepatitis C drug

(Reuters) - U.S. pharmacy benefit managers expect the launch of Merck & Co Inc's new hepatitis C pill to improve their leverage in price negotiations with drugmakers.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro